3,5-Disubstituted Pyrazole CHK1 Inhibitors for Resistant Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel compounds that can effectively inhibit CHK1 kinase activity to enhance cancer treatment, as some cancer cells exhibit insensitivity or resistance to chemotherapy and radiotherapy due to overactivation of CHK1 kinase.
Innovation Solution
Development of 3,5-disubstituted pyrazole compounds and their pharmaceutically acceptable forms as CHK1 kinase inhibitors, which can be used in pharmaceutical compositions for cancer treatment, either alone or in combination with other anticancer agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CHK1 kinase is overactivated in cancer cells, then cell survival and resistance to chemotherapy/radiotherapy are enhanced, but treatment efficacy is reduced
Solution Approach 1:
The patent applies preliminary anti-action by developing CHK1 kinase inhibitors that preemptively block the overactivated CHK1 pathway in cancer cells before chemotherapy or radiotherapy is administered. This preliminary inhibition prevents the DNA damage response mechanism from activating cell survival pathways, thereby sensitizing cancer cells to subsequent treatment and overcoming resistance.
2Productivity
If CHK1 kinase activity is inhibited, then cancer cell apoptosis is promoted and cell cycle progression is blocked, but DNA repair mechanisms may be compromised
Solution Approach 1:
The patent applies local quality by selectively inhibiting CHK1 kinase activity specifically in cancer cells that exhibit overactivation of this pathway, rather than universally blocking all DNA repair mechanisms. The inhibitors are designed to target the dysregulated CHK1 signaling in malignant cells while preserving normal cellular functions in healthy tissues, achieving localized therapeutic effect with minimal off-target impact on DNA repair integrity.
3Adaptability or versatility
If novel CHK1 inhibitors are developed, then treatment options for resistant cancer cells are expanded, but drug development complexity increases
Solution Approach 1:
The patent applies universality by developing a series of CHK1 kinase inhibitors with varying chemical structures (including pyrazole, pyridine, and other heterocyclic compounds) that all target the same CHK1 kinase enzyme. This multi-functional approach provides multiple compounds with similar therapeutic mechanisms, allowing selection of the most effective agent for different cancer types and resistance patterns, thereby expanding treatment options while managing development complexity through a focused target approach.
Data Source
AI summary
Compounds represented by Formula I in which A0-A2, R0-R6, L, Z and Q are defined herein. The compounds of Formula I are CHK 1 inhibitors. Therefore, the compounds can be used to treat diseases, disorders and conditions associated with continuous activation of CHK1 or with high internal DNA damage or injury during DNA replication, such as cancers.